Psoriasis treatment and nerve pain study
Part of Brain & nervous system, Pain, Skin clinical trials.
This study looks at how different psoriasis treatments affect nerve-related pain and sensitivity. It compares patients on biologic injections, standard pills, or creams to see if treatment type matters for pain and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have chronic plaque psoriasis
- You are currently on one of these treatments: an IL-17 inhibitor (like secukinumab or ixekizumab) for at least 8 weeks, or methotrexate or acitretin for at least 6 weeks, or you use only creams or no treatment (and haven't had systemic, biologic, or light therapy in the last 6 months)
- You do not have diabetes, nerve damage, kidney or liver failure, active infections or cancer, and you are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether IL-17 inhibitor medications can reduce inflammation in tendons and ligaments that is not visible on the skin but can be detected with a special ultrasound. It may be an option for people with moderate to severe psoriasis who have not had enough relief from creams or light therapy.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This study looks at how blood sugar control (including diabetes) changes immune cells in the skin for people with moderate to severe plaque psoriasis. It may help researchers understand what drives psoriasis and how it could respond to future treatments.
This study explores whether a protein called IL-17 might link skin/joint inflammation with depressive symptoms. If you have psoriasis or psoriatic arthritis and are starting a specific biologic (secukinumab, bimekizumab, or ixekizumab), this could help understand how treatment affects your mood.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
Hear when a new Chronic Plaque-type Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.